Biomarker Testing Market Report 2026

The biomarker testing market size has grown rapidly in recent years. It will grow from $19.75 billion in 2025 to $22.26 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, expansion of clinical research activities, rising adoption of molecular diagnostics, growing demand for targeted therapies, availability of advanced testing platforms.

The biomarker testing market size is expected to see rapid growth in the next few years. It will grow to $35.51 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing investments in personalized medicine, rising use of biomarkers in drug development, expansion of oncology and infectious disease testing, growing demand for minimally invasive diagnostics, advancements in multi-omics technologies. Major trends in the forecast period include increasing adoption of precision medicine diagnostics, rising use of companion diagnostics, growing integration of ai in biomarker analysis, expansion of liquid biopsy testing, enhanced focus on early disease detection.

The increasing cancer burden is expected to drive the growth of the biomarker testing market in the coming years. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The rising cancer burden is influenced by lifestyle factors such as poor diet, smoking, lack of physical activity, and excessive alcohol consumption. Biomarker testing enhances cancer detection by enabling early and accurate identification of disease-specific markers, thereby improving diagnostic precision. It also supports personalized treatment planning, leading to better patient outcomes and more effective healthcare management. For instance, in July 2024, according to the Australian Institute of Health and Welfare, a government agency, approximately 165,000 new cancer cases were diagnosed in 2023, with projections indicating around 204,000 cases annually by 2033, contributing to an estimated total of 1.9 million cancer cases between 2024 and 2033. Therefore, the growing cancer burden is driving the expansion of the biomarker testing market.

Key companies operating in the biomarker testing market are focusing on developing advanced technological solutions, such as immunohistochemistry (IHC) technology, to enhance diagnostic accuracy, enable early detection, and support personalized treatment approaches. Immunohistochemistry (IHC) technology is a laboratory technique that uses antibodies to detect specific proteins in tissue samples, facilitating the identification and visualization of biomarkers for disease diagnosis and research. For example, in July 2023, Quest Diagnostics Incorporated, a US-based medical laboratory company, launched a new tissue-based prostate cancer biomarker test through its AmeriPath business. The test leverages proprietary biomarkers EV1, EV2, and EV3 to improve diagnostic precision, differentiate aggressive forms of prostate cancer, enhance grading consistency, and guide appropriate treatment strategies for patients.

In August 2025, Quanterix Corp., a US-based life sciences company, acquired Emission Inc. for approximately $70 million. Through this acquisition, Quanterix aims to broaden its technology portfolio and market reach by integrating Emission’s advanced multiplex and multi-omic assay technologies, strengthening its position in the biomarker testing sector and driving growth through improved diagnostic capabilities and new market opportunities. Emission Inc. is a US-based biotechnology company specializing in multiplex and multi-omic assay solutions for biomarker testing.

Major companies operating in the biomarker testing market are Roche Diagnostics International Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company, GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Hologic Inc., Charles River Laboratories International Inc., PerkinElmer Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Myriad Genetics Inc., Guardant Health Inc., Sino Biological Inc., Proteome Sciences plc.

North America was the largest region in the biomarker testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biomarker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biomarker testing market by increasing costs of imported reagents, assay kits, sequencing instruments, analytical software, and laboratory automation systems. Diagnostic laboratories and research institutes in North America and Europe are most affected due to dependence on specialized imported consumables, while Asia-Pacific faces higher costs for instrument manufacturing and exports. These tariffs are increasing testing expenses and influencing research budgets. However, they are also encouraging localized reagent manufacturing, regional instrument assembly, and investment in domestic diagnostic innovation.

The biomarker testing market research report is one of a series of new reports that provides biomarker testing market statistics, including biomarker testing industry global market size, regional shares, competitors with a biomarker testing market share, detailed biomarker testing market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker testing industry. This biomarker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biomarker testing refers to the analysis of blood, tissue, or other body fluids to detect specific biological markers that indicate normal or diseased states. It plays a vital role in disease diagnosis, predicting disease progression, and enabling personalized treatment strategies.

The primary product types of biomarker testing include consumables, instruments, services, and others. Consumables are items that are used up during testing and require regular replacement, such as reagents, kits, or laboratory supplies. The technologies employed include polymerase chain reaction (PCR), next-generation sequencing (NGS), immunoassays, and others. Biomarker testing is applied in areas such as oncology, cardiology, neurology, infectious diseases, and more, serving end users including hospitals, diagnostic laboratories, research institutes, and others.

The biomarker testing market consists of revenues earned by entities by providing services such as clinical biomarker testing services, bioinformatics and data analysis services, sample collection and biobanking services, and companion diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The biomarker testing market includes sales of analytical instruments, imaging devices, lab-on-a-chip and microfluidic devices, and data acquisition and integration hardware. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.